ACELRX PHARMACEUTICALS INC (ACRX)
US00444T2096 - Common Stock
ACRX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. While ACRX seems to be doing ok healthwise, there are quite some concerns on its profitability. ACRX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ACRX had negative earnings in the past year.
In the past year ACRX has reported a negative cash flow from operations.
In the past 5 years ACRX reported 4 times negative net income.
In the past 5 years ACRX always reported negative operating cash flow.
1.2 Ratios
ACRX has a worse Return On Assets (-113.65%) than 84.31% of its industry peers.
ACRX has a Return On Equity of -144.70%. This is in the lower half of the industry: ACRX underperforms 68.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -113.65% | ||
| ROE | -144.7% | ||
| ROIC | N/A |
ROA(3y)-5.62%
ROA(5y)-22.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ACRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ACRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACRX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ACRX has more shares outstanding
ACRX has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -26.92, we must say that ACRX is in the distress zone and has some risk of bankruptcy.
ACRX's Altman-Z score of -26.92 is on the low side compared to the rest of the industry. ACRX is outperformed by 88.73% of its industry peers.
ACRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -26.92 |
ROIC/WACCN/A
WACC9.57%
2.3 Liquidity
A Current Ratio of 4.00 indicates that ACRX has no problem at all paying its short term obligations.
ACRX's Current ratio of 4.00 is in line compared to the rest of the industry. ACRX outperforms 55.39% of its industry peers.
A Quick Ratio of 4.00 indicates that ACRX has no problem at all paying its short term obligations.
ACRX has a Quick ratio (4.00) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4 | ||
| Quick Ratio | 4 |
3. Growth
3.1 Past
ACRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.88%, which is quite impressive.
ACRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -37.23%.
The Revenue for ACRX have been decreasing by -26.04% on average. This is quite bad
EPS 1Y (TTM)50.88%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q91.49%
Revenue 1Y (TTM)-37.23%
Revenue growth 3Y-8.23%
Revenue growth 5Y-26.04%
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 15.09% on average over the next years. This is quite good.
ACRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.49% yearly.
EPS Next Y72.27%
EPS Next 2Y34.78%
EPS Next 3Y22.12%
EPS Next 5Y15.09%
Revenue Next Year-91.49%
Revenue Next 2Y-52.31%
Revenue Next 3Y-25.27%
Revenue Next 5Y36.49%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ACRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ACRX's earnings are expected to grow with 22.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.78%
EPS Next 3Y22.12%
5. Dividend
5.1 Amount
No dividends for ACRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACELRX PHARMACEUTICALS INC
NASDAQ:ACRX (1/9/2024, 7:00:00 PM)
After market: 0.8719 +0.01 (+1.38%)0.86
+0.06 (+7.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap14.58M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -113.65% | ||
| ROE | -144.7% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4 | ||
| Quick Ratio | 4 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)50.88%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y72.27%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-37.23%
Revenue growth 3Y-8.23%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y